Evaluating the potential impact of the new Global Plan to Stop TB: Thailand, 2004-2005

Bulletin of the World Health Organization

Volumn 85, Issue 8, 2007, Pages 586-592

  Varma, Jay K ^a   Wiriyakitjar, Daranee ^b   Nateniyom, Sriprapa ^b   Anuwatnonthakate, Amornrat ^b   Monkongdee, Patama ^b   Sumnapan, Surin ^c   Akksilp, Somsak ^d   Sattayawuthipong, Wanchai ^e   Charunsuntonsri, Pricha ^f   Rienthong, Somsak ^b   Yamada, Norio ^g   Akarasewi, Pasakorn ^b   Wells, Charles D ^a   Tappero, Jordan W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c Chiang Rai Provincial Public Health Office   (Thailand)

^d Office of Disease Prevention and Control 7   (Thailand)

^e Phuket Provincial Health Office   (Thailand)

^f Bangkok Metropolitan Administration   (Thailand)

^g RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; STAVUDINE; ZIDOVUDINE;

COST-BENEFIT ANALYSIS; DRUG RESISTANCE; HEALTH CARE; HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMORBIDITY; COST OF ILLNESS; COUNSELING; DRUG SENSITIVITY; HEALTH CARE COST; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MICROSCOPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PREVALENCE; SMEAR; SPUTUM EXAMINATION; THAILAND; TUBERCULOSIS; X RAY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH PRIORITIES; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INTERINSTITUTIONAL RELATIONS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PRIVATE SECTOR; PROGRAM EVALUATION; PUBLIC SECTOR; RISK FACTORS; SENTINEL SURVEILLANCE; THAILAND; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

ASIA; EURASIA; SOUTHEAST ASIA; THAILAND;

EID: 34548257289     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.038067     Document Type: Article

References (15)

1. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002;359:775-80.
2. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-75.
3. World Health Organization. The Global Plan to Stop TB 2006-2015: actions for life towards a world free of tuberculosis. Geneva: WHO; 2006 (WHO/HTM/STB/2006.35).
4. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2005. Geneva: WHO; 2005. (WHO/HTM/TB/2005.349).
5. World Health Organization, Regional Office for South-East Asia. Third review of the national tuberculosis programme in Thailand, 17-28 November 2003. New Delhi: WHO; 2004 (SEA-TB-267).
6. World Health Organization. Public-private Mix for DOTS: practical tools to help implementation. Geneva: WHO; 2003 (WHO/CDS/TB/2003.325).
7. Martin DJ, Sim JG, Sole GJ, Rymer L, Shalekoff S, van Niekirk AB, et al. CD4+ lymphocyte count in African patients co-infected with HIV and tuberculosis. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:386-91.
8. Teck R, Ascurra O, Gomani P, Manzi M, Pasulani O, Kusamale J, et al. WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis 2005;9:258-62.
9. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, et al. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis 2003;187:1967-71.
10. Abouya L, Coulibaly IM, Wiktor SZ, Coulibaly D, N'kragbo M, N'gbo A, et al. The Côte d'Ivoire national HIV counseling and testing program for tuberculosis patients: implementation and analysis of epidemiologic data. AIDS 1998;12:505-12.
11. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
12. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;1:CD000171.
13. Stop TB New Diagnostics Working Group, Strategic plan 2006-2015. Available at: http://www.stoptb.org/wg/new_diagnostics/assets/documents/ SP%20Stop%20TB%20Dia%20WG%20-FINAL-Dec2005.pdf
14. Sawert H, Kongsin S, Payanandana V, Akarasewi P, Nunn PP, Raviglione MC. Costs and benefits of improving tuberculosis control: the case of Thailand. Soc Sci Med 1997;44:1805-16.
15. Kamolratanakul P, Hiransithikul N, Singhadong N. Cost analysis of different types of tuberculosis patients at tuberculosis centers in Thailand. Southeast Asian J Trop Med Public Health 2002;33:321-30.